CHICAGO, Illinois, September 15, 2015 – A recent assessment of R&D success rates reveals that large molecules continue to outperform small molecules in most phases of Development. For example, in Phase II small molecules have a 24% rate of success vs. 40% for large molecules; the difference in Phase III is 65% for small molecules vs. 79% for large. The only phase where there is no significant variance is the final, Registration phase.
This is based on data released by the Pharmaceutical Benchmarking Forum, a group of large biopharma which integrates R&D productivity data and analyzes performance and trends.
Notes:
“Small” refers to chemical molecules; “Large” refers to biologics (including peptides); vaccines are excluded; “Industry Portrait” means all data from contributing companies is combined into single analysis (as if they were a single company)
Pure method employed: for given molecule size, all in-licensed/acquired NMEs excluded from calculation for the phase in which they entered, but included for all subsequent phases
Method to calculate Success Rate: (number of small molecule successes in phase) / ((number of small molecule terminations in phase) + (number of small molecule successes in phase)); same method applied for large molecules
Percent calculated to achieve 1 Approval for small molecules: apply multiplier method for each phase for small molecules (e.g., Phase 2 rate starts with Industry Phase 2 success rate and multiplies all subsequent phase success rates); same method applied for large molecules The PBF was organized in 1997. In 2015 the following submitted R&D data: AbbVie, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck Research Labs, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda.
About the Pharmaceutical Benchmarking Forum (PBF)
Formed in 1997, the Pharmaceutical Benchmarking Forum (PBF) consists of many of the world’s leading pharmaceutical companies and has emerged as the Industry’s premier source on R&D performance metrics. Its focus is to employ careful analysis of R&D data to compare performance, examine Industry trends, answer critical business questions, and identify best practices. The scope of the Forum extends across the full R&D spectrum, from a detailed examination of Discovery to an annual review of R&D performance, including productivity, success rates, cycle time, and pipeline. In addition to its flagship study on R&D performance, the PBF sponsors additional studies on topics of interest to the Industry. These specialist studies range from the evaluation of project cost to an in-depth look at biologics R&D.
About KMR Group
KMR has been working exclusively in the biopharmaceutical R&D industry since the early 1990s. KMR is a leader in benchmarking, analytics and performance management as well as a developer of proprietary analytics software. With an exclusive focus on biopharmaceutical R&D and unrivaled commitment to data quality, KMR provides industry with the experience and knowledge to produce clear and uncompromising results in the form of reports, tools and presentations. We use our extensive, unparalleled datasets and experience within the industry to add value to the most pressing business questions. Please visit our website at https://kmrgroup.com
Help employers find you! Check out all the jobs and post your resume.
This is based on data released by the Pharmaceutical Benchmarking Forum, a group of large biopharma which integrates R&D productivity data and analyzes performance and trends.
Notes:
“Small” refers to chemical molecules; “Large” refers to biologics (including peptides); vaccines are excluded; “Industry Portrait” means all data from contributing companies is combined into single analysis (as if they were a single company)
Pure method employed: for given molecule size, all in-licensed/acquired NMEs excluded from calculation for the phase in which they entered, but included for all subsequent phases
Method to calculate Success Rate: (number of small molecule successes in phase) / ((number of small molecule terminations in phase) + (number of small molecule successes in phase)); same method applied for large molecules
Percent calculated to achieve 1 Approval for small molecules: apply multiplier method for each phase for small molecules (e.g., Phase 2 rate starts with Industry Phase 2 success rate and multiplies all subsequent phase success rates); same method applied for large molecules The PBF was organized in 1997. In 2015 the following submitted R&D data: AbbVie, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck Research Labs, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda.
About the Pharmaceutical Benchmarking Forum (PBF)
Formed in 1997, the Pharmaceutical Benchmarking Forum (PBF) consists of many of the world’s leading pharmaceutical companies and has emerged as the Industry’s premier source on R&D performance metrics. Its focus is to employ careful analysis of R&D data to compare performance, examine Industry trends, answer critical business questions, and identify best practices. The scope of the Forum extends across the full R&D spectrum, from a detailed examination of Discovery to an annual review of R&D performance, including productivity, success rates, cycle time, and pipeline. In addition to its flagship study on R&D performance, the PBF sponsors additional studies on topics of interest to the Industry. These specialist studies range from the evaluation of project cost to an in-depth look at biologics R&D.
About KMR Group
KMR has been working exclusively in the biopharmaceutical R&D industry since the early 1990s. KMR is a leader in benchmarking, analytics and performance management as well as a developer of proprietary analytics software. With an exclusive focus on biopharmaceutical R&D and unrivaled commitment to data quality, KMR provides industry with the experience and knowledge to produce clear and uncompromising results in the form of reports, tools and presentations. We use our extensive, unparalleled datasets and experience within the industry to add value to the most pressing business questions. Please visit our website at https://kmrgroup.com
Help employers find you! Check out all the jobs and post your resume.
